PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397295
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1397295
Fairfield Market Research, a renowned provider of industry analysis reports, has recently released a comprehensive study on the Anti-Vascular Endothelial Growth Factor Therapeutics Market. The report reveals that the global sales of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) therapies reached US$ 12.1 billion in 2024. The market is projected to experience a steady growth trajectory during the period from 2024 to 2031, slightly higher than historical growth rates.
The Anti-Vascular Endothelial Growth Factor Therapeutics Market is driven by several key factors:
Despite the promising prospects, there are challenges and limitations to consider:
Anti-Vascular Endothelial Growth Factor Therapeutics have shown significant effectiveness in treating diabetic retinopathy (DR), a common microvascular complication of diabetes. DR is a leading cause of new instances of blindness in working-age individuals. The use of Anti-VEGF inhibitors delivered through intraocular injection has improved visual outcomes in patients with DR.
The global population aged 60 and above is steadily increasing. The World Health Organization (WHO) estimates that the elderly population surpassed that of children under the age of five. As the elderly population grows, the incidence of eye problems is expected to rise, further boosting the demand for Anti-VEGF therapies.
U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market: The U.S. market is driven by factors such as the rising prevalence of cardiovascular illnesses, increased obesity risk, growing disposable incomes, and a competitive landscape with multiple market players.
U.K. Anti-Vascular Endothelial Growth Factor Therapeutics Market: The U.K. market is influenced by evolving healthcare trends and a focus on innovative treatments.
Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market: Japan's market is characterized by a growing aging population and a strong emphasis on healthcare advancements.
Key players in the Anti-Vascular Endothelial Growth Factor Therapeutics Market include: F. Hoffmann-La Roche Ltd., Biogen, Pfizer, Inc., CoherusBioSciences, and Amgen, Inc. These companies are at the forefront of research, development, and innovation in the field, driving the growth and evolution of Anti-VEGF therapies.